NCT03265782

Brief Summary

Comparison between the safety and efficacy of oral paracetamol and oral ibuprofen in treatment of Patent Ductus Arteriosus (PDA) in premature infants

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
30

participants targeted

Target at below P25 for phase_4

Timeline
Completed

Started Jun 2015

Typical duration for phase_4

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

March 10, 2015

Completed
3 months until next milestone

Study Start

First participant enrolled

June 1, 2015

Completed
2.2 years until next milestone

First Posted

Study publicly available on registry

August 29, 2017

Completed
3 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2017

Completed
4 months until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2018

Completed
Last Updated

August 29, 2017

Status Verified

August 1, 2017

Enrollment Period

2.3 years

First QC Date

March 10, 2015

Last Update Submit

August 28, 2017

Conditions

Keywords

efficacysafetyparacetamolibuprofenPDApreterms

Outcome Measures

Primary Outcomes (1)

  • closure of PDA

    Echo confirmed closure

    6 days

Study Arms (2)

ibuprofen group

EXPERIMENTAL

treatment of pda with oral ibuprofen with a loading dose 10 mg/kg/ds in the first day followed by 5 mg/kg/ds in the second ant third days then a follow up echo is done

Drug: ibuprofen

paracetamol group

EXPERIMENTAL

treatment of pda with oral paracetamol with dose of 15 mg/kg/ds every 6 hours for 3 days then a follow up echo is done

Drug: paracetamol

Interventions

drug was adminstred with a loading dose 10 mg/kg/day followed by 5 mg/kg/day in 2 doses with 24 hrs apart for 3 days

Also known as: brufen
ibuprofen group

drug was administred for 3 consequetive days in a dosev 15 mg/kg/dose every 6 hrs and follow up echo was done after 3 days

Also known as: cetal
paracetamol group

Eligibility Criteria

Age28 Weeks - 35 Weeks
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)

You may qualify if:

  • Gestational age ≤ 35 weeks
  • Aged 2-7 days with color Doppler echocardiographic evidence of PDA
  • Urine output more than 1 ml/kg/hr
  • Creatinine concentration level less than 1.8 mg/dl

You may not qualify if:

  • Neonates who have one or more of the following criteria were excluded from the study:
  • Congenital heart diseases of any type including
  • Pulmonary stenosis
  • Anomalus in pulmonary venous drainage
  • Ventricular septal defect
  • Major congenital anomalies as hydrops fetalis
  • Low platelets count (less than 60, 000/mm3)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (1)

  • El-Farrash RA, El Shimy MS, El-Sakka AS, Ahmed MG, Abdel-Moez DG. Efficacy and safety of oral paracetamol versus oral ibuprofen for closure of patent ductus arteriosus in preterm infants: a randomized controlled trial. J Matern Fetal Neonatal Med. 2019 Nov;32(21):3647-3654. doi: 10.1080/14767058.2018.1470235. Epub 2018 May 9.

MeSH Terms

Conditions

Ductus Arteriosus, Patent

Interventions

IbuprofenAcetaminophen

Condition Hierarchy (Ancestors)

Heart Defects, CongenitalCardiovascular AbnormalitiesCardiovascular DiseasesHeart DiseasesCongenital AbnormalitiesCongenital, Hereditary, and Neonatal Diseases and Abnormalities

Intervention Hierarchy (Ancestors)

PhenylpropionatesAcids, CarbocyclicCarboxylic AcidsOrganic ChemicalsAcetanilidesAnilidesAmidesAniline CompoundsAmines

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
pricipal investigator

Study Record Dates

First Submitted

March 10, 2015

First Posted

August 29, 2017

Study Start

June 1, 2015

Primary Completion

September 1, 2017

Study Completion

January 1, 2018

Last Updated

August 29, 2017

Record last verified: 2017-08